Literature DB >> 22787510

Correspondence (letter to the editor): Critical remarks.

Thomas Küpper, U Gieseler, Herbert Löllgen.   

Abstract

Mesh：

Year:  2012        PMID： 22787510      PMCID： PMC3392001          DOI： 10.3238/arztebl.2012.0445b

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Training in normobaric hypoxia and its effects on acute mountain sickness after rapid ascent to 4559 m.

Authors:  Kai Schommer; Neele Wiesegart; Elmar Menold; Ute Haas; Katrin Lahr; Hermann Buhl; Peter Bärtsch; Christoph Dehnert
Journal:  High Alt Med Biol       Date:  2010       Impact factor: 1.981

2.  Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness.

Authors:  Andrew M Luks; Scott E McIntosh; Colin K Grissom; Paul S Auerbach; George W Rodway; Robert B Schoene; Ken Zafren; Peter H Hackett
Journal:  Wilderness Environ Med       Date:  2010-03-10       Impact factor: 1.518

3.  Basic medical advice for travelers to high altitudes.

Authors:  Kai Schommer; Peter Bärtsch
Journal:  Dtsch Arztebl Int       Date:  2011-12-09       Impact factor: 5.594

4.  Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.

Authors:  Buddha Basnyat; Jeffrey H Gertsch; Peter S Holck; E William Johnson; Andrew M Luks; Benjamin P Donham; Ross J Fleischman; Daniel W Gowder; Jason S Hawksworth; Brett T Jensen; Richard J Kleiman; Adam H Loveridge; Elizabeth B Lundeen; Sheri L Newman; Jesse A Noboa; Daniel P Miegs; Kenneth A O'Beirne; Kelly B Philpot; Miriam N Schultz; Matthew C Valente; Mandie R Wiebers; Erik R Swenson
Journal:  High Alt Med Biol       Date:  2006       Impact factor: 1.981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.